Scope and patent-claim landscape analysis for US Patent 6,812,238 (United States Drug Patent)
US 6,812,238 is a small-molecule composition and method-of-treatment patent directed to a highly substituted triazole “butan-2-ol” scaffold linked through the triazole nitrogen to a fixed “Q” moiety containing a cyanophenyl substituent on a thiazole and a 2,5-difluorophenyl group. Claim scope is broad at the structural core level but meaningfully constrained by (i) the exact Q moiety and its link-through triazole nitrogen, (ii) the defined R1/R2/R3/X substitution frameworks, and (iii) multiple dependent claims narrowing to specific substitution patterns and specific on-claim example salts. The enforceable hook is the combination of a defined core chemistry plus flexible substituent classes that cover a large parameter space of related analogs, while still requiring the specific triazole-linked “Q” identity and the defined difluoro-phenyl/butan-2-ol stereochemical and connectivity features.
What does US 6,812,238 claim cover, and how broad is the core chemistry?
Short answer: The patent claims a family of compounds of “formula (I)” with a fixed Q moiety and variable substituents (R1, R2, R3, X−), plus specific enumerated triazolium chloride salts and a use claim for fungal infections. The structural core is stringent; the allowable variation sits mainly on peripheral substituents and an anion/salt selection.
Claim 1 architecture (formula I)
Claim 1 is the master claim and defines:
- A compound of formula (I)
- Fixed identity of Q:
Q = 3-[4-(4-cyanophenyl)thiazol-2-yl)]-2-(2,5-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-butan-2-ol moiety
- Connectivity: Q is linked to the remainder of formula (I) by a nitrogen in the triazole
- Variable groups:
- R1: hydrogen or alkyl
- R2: hydrogen, alkyl, alkylcarbonyloxyalkyl, alkoxycarbonyl, alkylcarbonyl, mono- or dialkylaminoalkylcarbonyloxyalkyl
- R3: pyridin-2-yl or substituted pyridin-2-yl (with an enumerated substituent list)
- X−: pharmaceutically acceptable anion or a pharmaceutically acceptable salt
What is fixed vs variable
- Fixed (high barrier to design-around):
- the presence of the 4-cyanophenyl substituted thiazole at the 3-position of Q
- the 2,5-difluorophenyl substitution at the 2-position of Q
- the 1-(1H-1,2,4-triazol-1-yl) identity within Q
- the “butan-2-ol” motif
- linking through a triazole nitrogen
- Variable (lower barrier):
- R1 (H/alkyl)
- R2 (H/alkyl and multiple protected/functional ester and aminoalkyl carbonate-like classes)
- R3: substituted pyridin-2-yl with a closed list of allowed substituents
- X−: anion/salt selection (still bounded to “pharmaceutically acceptable”)
Dependent claims tighten the scope
Claim 2 narrows R3 to substituted pyridin-2-yl.
Claims 3-7 introduce further formula II/III sub-classes controlling:
- allowed R4/R5 substituents on the pyridine ring (again from enumerated groups)
- R6 substitution class that covers hydroxy and broad “hydrolizable radical” acyl/aminocarboxylate-type substituents
This means the patent has two layered scope boundaries:
- the master scaffold restrictions (Q and connection)
- the substituent-class restrictions in nested formulae (II/III)
Which chemical elements in US 6,812,238 are most likely to be infringement-critical?
Short answer: The Q moiety identity and the “linked by a nitrogen in the triazole” connectivity, together with the 2,5-difluorophenyl and 4-cyanophenyl-thiazole substitutions, are the highest-probability infringement anchors. Secondary anchors are the R3 (pyridin-2-yl) framework and the anion/salt embodiment for the enumerated triazolium chloride salts.
Highest-risk features for generics/analogs
-
Q identity and composition
Any analog that keeps or substitutes away the thiazole-cyanophenyl, difluorophenyl, and butan-2-ol/triazole framework is structurally closer. Removing one of these would likely fall outside formula I as written.
-
Triazole-nitrogen linkage requirement
Claim 1 explicitly states that Q is linked to the remainder “by a nitrogen in the triazole.” A competitor that re-engineers the linker so Q attaches through oxygen or carbon rather than a triazole N would likely attempt to avoid this element.
-
R3 must be pyridin-2-yl (or substituted pyridin-2-yl)
The claim does not allow other heteroaryl rings. Even if a competitor keeps the remainder chemistry, replacing the pyridin-2-yl with pyridin-3-yl, pyrimidinyl, quinolinyl, etc., is a likely design-around.
-
Substituent set on R3 is closed-list
The “when R3 is substituted pyridin-2-yl” clause enumerates substituents allowed: halogen, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, carboxy, alkyloxycarbonyl, cyano, trifluoromethyl, trifluoromethoxy, nitro, aminosulfonyl, alkylaminocarboyloxyalkyl, sulfo, alkylcarbonyloxyalkyl and aminoalkylcarbonyloxyalkyl.
Any R3 substitution outside that list is outside the literal claim 1 structure as described.
Enumerated chloride salt embodiments (claims 16-17)
Claim 16 lists three specific compounds described as triazolium chloride dihydrochloride / hydrochloride variants. Claim 17 repeats one specific member exactly.
From an infringement standpoint, these provide:
- explicit target embodiments that are easier to compare molecule-by-molecule
- a narrower “exact match” set in addition to the broader formula I family
Method-of-use claim (claim 19)
Claim 19 covers:
- “treating fungal infections”
- “administering… an effective amount” of a claim 1 compound
Use claims can be harder to invalidate if the compound itself is protected and if clinical/label indications align. It also creates a pathway for enforcement even if an accused product is argued to be a salt-form variant of a claimed compound (if the active ingredient still falls under claim 1).
What is the effective claim breadth by substitution variables (R1, R2, R3, R6, X−)?
Short answer: The patent’s chemical space is broad around R2 and R6 (protected ester/aminoalkylcarbonyloxy families) and uses a limited but still wide closed list for substituted pyridin-2-yl at R3. R1 is modest (H/alkyl). X− is broad on “pharmaceutically acceptable anion” but does not eliminate core scaffold constraints.
R1 (claim 1 and dependent claim 10-11)
- R1 = hydrogen or alkyl
- Dependent claims narrow to methyl in claim 11
Implication: A competitor with a non-methyl alkyl at R1 could still fall in claim 1 (if alkyl other than methyl), but claim 1 is already broad enough to cover “alkyl” generally.
R2 (claim 1 and dependent claims 12-13)
- R2 can be hydrogen, alkyl, or multiple functional classes:
- alkylcarbonyloxyalkyl
- alkoxycarbonyl
- alkylcarbonyl
- mono- or dialkylaminoalkylcarbonyloxyalkyl
Dependent claims specify R2 = alkyl (claim 13). That still leaves multiple alkyls within the main claim.
Implication: If the compound class is intended to represent prodrug-like or convertible groups, the claim language is designed to catch both “direct” and “masked” functionalities that revert in vivo (the “hydrolizable radical” language appears in the R6-dependent chain).
R3 substituents (claim 1 and dependent claims 2-7)
R3 is pyridin-2-yl or substituted pyridin-2-yl, with substituent options enumerated in claim 1 and narrowed in dependent claims via R4/R5 (formula II/III).
Implication: The R3 list is a key determinant of design-around: a competitor can attempt to choose a substituent not on the allowed list while otherwise keeping Q and the rest of the scaffold.
R6 (claim 3-9)
Claim 3 introduces R6 selected from many groups including:
- hydroxy
- alkoxycarbonylalkylamino
- alkoxycarbonylamino
- amino
- alkylamino
- alkylcarbonyloxy
- alkoxycarbonylalkylaminoalkylcarbonyloxy
- alkoxycarbonylamino-alkylcarbonyloxy
- alkylaminoalkylcarbonyloxy
- aminoalkylcarbonyloxy
- alkylcarbonylamino
- alkylcarbonylalkylamino
- acyloxy / acylamino / acylalkylamino where “acyl group is a hydrolizable radical”
Dependent claims narrow R6 to alkylamino, alkylcarbonyloxy, alkylaminoalkylcarbonyloxy or aminoalkylcarbonyloxy (claim 8), and then to alkylaminoalkylcarbonyloxy (claim 9).
Implication: R6 scope is built to include both free amines and hydrolizable “prodrug-like” derivatives.
X− (claim 1)
X− is any pharmaceutically acceptable anion; claim 16-17 specify chloride forms.
Implication: Even if a competitor uses bromide, tosylate, sulfate, etc., literal scope still includes an “X− pharmaceutically acceptable anion,” as long as the cationic core is unchanged and falls under claim 1’s Q/R1/R2/R3/R6 constraints.
Which specific compounds are explicitly claimed in US 6,812,238 (claims 16-17)?
Short answer: The patent explicitly lists three triazolium chloride salt compounds in claim 16 and one specific member in claim 17.
Claim 16 explicit compounds (three enumerated salt embodiments)
The three compounds are described as:
- 1-[[N-methyl-N-3-[(methylamino)acetoxyethyl]pyridin-2-yl]carbamoyloxy]ethyl-1-[(2R,3R)-2-(2,5-difluorophenyl)-2-hydroxy-3-[4-(4-cyanophenyl)thiazol-2-yl]butyl]-1H-[1,2,4]triazol-4-ium chloride dihydrochloride
- the same core with “acetoxymethyl” substitution at the pyridine side chain and hydrochloride form
- the same core with an “acetoxymethyl” variant and a different chloride salt description
Claim 17 explicit compound (one enumerated salt embodiment)
- 1-[[N-methyl-N-3-[(methylamino)acetoxymethyl]pyridin-2-yl]carbamoyloxy]ethyl-1-[(2R,3R)-2-(2,5-difluorophenyl)-2-hydroxy-3-[4-(4-cyanophenyl)thiazol-2-yl]butyl]-1H-[1,2,4]triazol-4-ium chloride hydrochloride
Why these matter
- They provide a clean infringement map for any accused product marketed as the same salt form.
- They also reinforce that the patent’s variable R6 and side-chain functionality includes acetoxyethyl/acetoxymethyl patterns, consistent with hydrolizable prodrug functionality.
What is the infringement vs invalidity posture implied by the claim set (composition vs method)?
Short answer: The patent uses both (i) compound structure claims and (ii) a fungal-infection treatment method claim. This creates dual enforcement pathways: product infringement for compound claims and use infringement for method-of-use.
Composition claim stack
- Claim 1: broad family structure
- Claims 2-7: narrowing sub-classes based on R3/R4/R5/R6 patterns
- Claims 16-17: fixed enumerated chloride salts
- Claim 18: pharmaceutical composition containing a claim 1 compound
Method claim
- Claim 19: treating fungal infections by administering an effective amount
Practical litigation leverage created by dependent claim patterns
Dependent claims that specify:
- R4/R5 permitted substituents on pyridine
- R6 selection including hydrolizable acyl groups
- R1 = methyl or R2 = alkyl
- specific stereochemical configuration shown in enumerated salts (2R,3R in claims 16-17)
These provide layered fallbacks if an accused product is close but not identical:
- literal infringement may hinge on the exact allowed substitution pattern
- even if a challenger argues certain elements fall outside formula I, the dependent claim set can create partial matches if the accused product aligns to the narrower embodiment
How does US 6,812,238 compare to a typical triazole antifungal patent estate?
Short answer: Unlike broad “triazole antifungal” functional language, this patent is chemistry-driven. It is not claiming “any antifungal triazole,” but instead a defined triazole-butanol scaffold with a specific Q thiazole/cyanophenyl and difluorophenyl package, plus prodrug-capable side chains.
Key differentiator
Many triazole antifungal patents use broad Markush structures; here, the language locks in:
- exact Q identity
- triazole N-linked connectivity
- fixed “4-cyanophenyl-thiazole” and “2,5-difluorophenyl” segments
- enumerated substitution lists for R3 and R4/R5
- explicit stereochemistry in enumerated salts
This reduces “conceptual overlap” with other antifungals that may share only a triazole headgroup.
What Orange Book status exists for US 6,812,238?
No Orange Book status can be determined from the information provided. The patent number alone is insufficient to map to an Orange Book NDA without the NDA/active ingredient link.
What generic entry risks exist for products with similar scaffolds?
Short answer: The largest generic entry risk is for molecules that keep the Q moiety, the triazole N-linkage, and the pyridin-2-yl (R3) framework, while varying only permitted R1/R2/R3 substituent members and selecting any pharmaceutically acceptable anion.
High-risk “design-around failures”
- Replacing the anion (X−) is unlikely to avoid claim 1 if the active cation remains within the formula I structure and X− stays pharmaceutically acceptable.
- Swapping side-chain protecting groups may still fall within R2/R6 if the substitution is in the enumerated functional classes (including hydrolizable radical acyl groups).
Lower-risk “design-around wins”
- Changing the linkage point so Q is not linked through a triazole nitrogen
- Replacing pyridin-2-yl (R3) with another ring (even another pyridine position) if it falls outside “pyridin-2-yl”
- Choosing R3/R4/R5 substituents not in the enumerated lists
Key takeaways
- US 6,812,238 claims a defined triazole-butan-2-ol antifungal scaffold centered on a fixed Q moiety that includes a 4-cyanophenyl substituted thiazole and a 2,5-difluorophenyl group.
- Claim 1 is broad in peripheral substituent classes (R2, R6, and salt anion X−), but strict on core identity and connectivity: Q is linked to the remainder via a triazole nitrogen.
- Dependent claims and formula II/III sub-classes tighten R3 (pyridin-2-yl) substituent choices via closed enumerations and cover hydrolizable radical acyl/prodrug-like functionality in R6.
- Claims 16-17 provide three explicit triazolium chloride salt embodiments and one repeated in claim 17, including stereochemical specification (2R,3R) in those enumerated examples.
- Claim 18 adds pharmaceutical composition coverage and claim 19 adds a fungal infection method-of-use coverage, enabling dual enforcement routes.
FAQs
1) Does US 6,812,238 cover different pharmaceutically acceptable anions?
Yes. Claim 1 defines X− as a pharmaceutically acceptable anion or pharmaceutically acceptable salt, while claims 16-17 also enumerate specific chloride salt forms.
2) Are prodrug-like ester/amino-acyl derivatives covered?
Yes. R2 includes alkylcarbonyloxyalkyl and alkoxycarbonyl/alkylcarbonyl types, and R6 explicitly includes acyl derivatives where the acyl group is a hydrolizable radical.
3) Can a competitor avoid the patent by changing the pyridine substituent pattern?
Only if the new substituents fall outside the enumerated substituent sets for R3 (and R4/R5 in the dependent formulae). The patent requires pyridin-2-yl (or substituted pyridin-2-yl), with allowed substituent categories listed in the claims.
4) Is stereochemistry material to the broad claim set?
Claim 1 describes the formula without the explicit stereochemical label you provided for the enumerated salts, but claims 16-17 include (2R,3R) in the explicitly listed chloride embodiments. The broader claim 1 still requires the defined scaffold identity and formula constraints.
5) Is the method-of-use claim limited to a specific route of administration or fungal species?
No. Claim 19 is limited to treating fungal infections by administering an effective amount of a claim 1 compound; the route and fungal species are not specified in the provided claim text.
References (APA)
- US Patent 6,812,238. (text provided in prompt).
